Indeed, SMAD7, which inhibits TGFβ signalling and is expressed at high levels in the intestines of patients with IBD,64 has been shown to be an effective therapeutic target via an antisense oligonucleotide (Mongersen) that binds to and degrades SMAD7 mRNA.65 The gene discussed is TGFB1; the disease is inflammatory bowel disease.